(Q38223249)

English

Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation

scientific article published on 26 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Bradley J Scott

1

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Agnes V Klein

2

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Jian Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

publication date

26 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

55 Suppl 3

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

S123-32

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Therapeutic antibodies: past, present and future.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Therapeutic monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Impact of Glycosylation on Effector Functions of Therapeutic IgG

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

What do prescribers think of biosimilars?

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

An engineered human IgG1 antibody with longer serum half-life.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Rheumatoid arthritis disease measurement: a new old idea

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Therapeutic antibodies for autoimmunity and inflammation

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

A Role for Protein Misfolding in Immunogenicity of Biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.339

21 January 2018

Identifiers

10.1002/JCPH.339

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38223249&oldid=1748172297"